Joe Biden Prostate Cancer Treatment Update
Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 10, 2026
The event has negligible direct market impact, as it concerns the personal health of a former officeholder rather than any policy, corporate or monetary decision. Any effect is limited to marginal attention on prostate cancer screening, diagnostics and treatment demand, and on the scheduled release of Biden's memoir.
Former United States President Joe Biden, 83, disclosed in a social media post on 8 September 2026, marking Prostate Cancer Awareness Month, that the radiation treatment he received for his aggressive prostate cancer last autumn worked as intended. Biden was diagnosed in May 2025 with an aggressive, hormone-sensitive form of prostate cancer that had already metastasised to his bones. He did not claim to be cancer-free or in remission, and his office provided no further clinical details or indication of a change in his ongoing care plan. In the same message, Biden urged American men to discuss prostate cancer screening with their doctors, saying men at average risk should begin around age 50, Black men at 45 or earlier, and men with a father or brother who had the disease at 45 or earlier. He cited American Cancer Society figures that more than 330,000 American men are expected to be diagnosed with prostate cancer in 2026, and noted that early detection yields a five-year survival rate close to 100 percent. Biden thanked the doctors, nurses and other medical professionals who have cared for him, and said he continues to work on his memoir, Promise Me, America, scheduled for release on 17 November 2026 by Little, Brown and Company. Family members have previously commented publicly on his condition, with Hunter Biden describing the pain as debilitating and Jill Biden saying she believes he will live with cancer for the rest of his life.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard